Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
Rubatto M, Fava P, Stanganelli I, Ribero S, Pigozzo J, Di Giacomo AM, Ridolfi L, Tronconi MC, Trojaniello C, Bersanelli M, Garutti M, Indini A, De Risi I, De Tursi M, Merelli B, Morgese F, Occelli M, Cappellini GCA, Poletto S, Fedele D, Brugnara S, Frisinghelli M, Formisano L, Conca R, Tucci M, Russillo M, Ceroni L, Queirolo P, Targato G, Strippoli S, Mandalà M, Guida M, Quaglino P. Rubatto M, et al. Among authors: russillo m. Eur J Cancer. 2023 Jul;187:25-35. doi: 10.1016/j.ejca.2023.03.020. Epub 2023 Mar 23. Eur J Cancer. 2023. PMID: 37099946
The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey.
Di Noia V, Renna D, Barberi V, Di Civita M, Riva F, Costantini G, Aquila ED, Russillo M, Bracco D, La Malfa AM, Giannarelli D, Cognetti F. Di Noia V, et al. Among authors: russillo m. Eur J Cancer. 2021 Aug;153:260-264. doi: 10.1016/j.ejca.2021.05.006. Epub 2021 May 26. Eur J Cancer. 2021. PMID: 34183225 Free PMC article.
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Fabi A, Metro G, Papaldo P, Mottolese M, Melucci E, Carlini P, Sperduti I, Russillo M, Gelibter A, Ferretti G, Tomao S, Milella M, Cognetti F. Fabi A, et al. Among authors: russillo m. Cancer Chemother Pharmacol. 2008 Sep;62(4):717-25. doi: 10.1007/s00280-007-0650-1. Epub 2007 Dec 6. Cancer Chemother Pharmacol. 2008. PMID: 18071704 Clinical Trial.
Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.
Metro G, Fabi A, Mirri MA, Vidiri A, Pace A, Carosi M, Russillo M, Maschio M, Giannarelli D, Pellegrini D, Pompili A, Cognetti F, Carapella CM. Metro G, et al. Among authors: russillo m. Cancer Chemother Pharmacol. 2010 Jan;65(2):391-7. doi: 10.1007/s00280-009-1155-x. Epub 2009 Oct 22. Cancer Chemother Pharmacol. 2010. PMID: 19847425 Clinical Trial.
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.
Cuppone F, Bria E, Vaccaro V, Puglisi F, Fabi A, Sperduti I, Carlini P, Milella M, Nisticò C, Russillo M, Papaldo P, Ferretti G, Aapro M, Giannarelli D, Cognetti F. Cuppone F, et al. Among authors: russillo m. J Exp Clin Cancer Res. 2011 May 12;30(1):54. doi: 10.1186/1756-9966-30-54. J Exp Clin Cancer Res. 2011. PMID: 21569417 Free PMC article.
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.
Fabi A, Russillo M, Ferretti G, Metro G, Nisticò C, Papaldo P, De Vita F, D'Auria G, Vidiri A, Giannarelli D, Cognetti F. Fabi A, et al. Among authors: russillo m. BMC Cancer. 2012 Oct 19;12:482. doi: 10.1186/1471-2407-12-482. BMC Cancer. 2012. PMID: 23083011 Free PMC article.
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.
Vici P, Pizzuti L, Sperduti I, Frassoldati A, Natoli C, Gamucci T, Tomao S, Michelotti A, Moscetti L, Gori S, Baldini E, Giotta F, Cassano A, Santini D, Giannarelli D, Di Lauro L, Corsi DC, Marchetti P, Sini V, Sergi D, Barba M, Maugeri-Saccà M, Russillo M, Mentuccia L, D'Onofrio L, Iezzi L, Scinto AF, Da Ros L, Bertolini I, Basile ML, Rossi V, De Maria R, Montemurro F. Vici P, et al. Among authors: russillo m. Oncotarget. 2016 Apr 5;7(14):17932-44. doi: 10.18632/oncotarget.7480. Oncotarget. 2016. PMID: 26910921 Free PMC article.
63 results